Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

The purpose of this trial is to test a deescalated 3-fraction stereotactic body radiotherapy (SBRT) regimen to 45 Gray (Gy) in 3 fractions for centrally located thoracic tumors.

Trial Details

NCT ID
NCT04210492
Phase
PHASE1 / PHASE2
Sponsor
Yale University
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • 45 Gray (Gy) regimen
Locations (sample)
  • Greenwich, Connecticut, United States|41.02649,-73.62846
  • Guilford, Connecticut, United States|41.28899,-72.68176
  • Hamden, Connecticut, United States|41.39593,-72.89677
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Trumbull, Connecticut, United States|41.24287,-73.20067

Key Eligibility Criteria

  • Lung tumors will be ≤ 5 cm and centrally located, meaning any portion of gross tumor volume located within 2 cm of (but not abutting) the proximal …
  • ECOG Performance Status of 0-2
  • Patients must sign a study-specific consent form.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →